 Connection
Godela Brosnahan to Humans
This is a "connection" page, showing publications Godela Brosnahan has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.210 |
|
|
|
-
Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 04; 79(4):518-526.
Score: 0.019
-
Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2021; 17(3):228-237.
Score: 0.018
-
Brosnahan GM, Moore CG, Abebe KZ. In Reply to 'Artificial Intelligence Can Predict GFR Decline During the Course of ADPKD' and 'Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD'. Am J Kidney Dis. 2018 06; 71(6):913.
Score: 0.015
-
Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676.
Score: 0.015
-
Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
Score: 0.015
-
Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
Score: 0.014
-
Brosnahan G. Treatment of hypertension in chronic kidney disease: does one size fit all? A narrative review from a nephrologist's perspective. Curr Hypertens Rev. 2014; 10(3):155-65.
Score: 0.011
-
Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? South Med J. 2010 Mar; 103(3):222-30.
Score: 0.009
-
Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J. 2010 Feb; 103(2):140-6.
Score: 0.009
-
Banerjee S, Brosnahan G. Polymyalgia rheumatica in a renal transplant patient. J Ark Med Soc. 2008 Nov; 105(5):115-7.
Score: 0.008
-
Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant. 2008 Oct; 23(10):3356-8.
Score: 0.008
-
Brosnahan GM. Volume progression in polycystic kidney disease. N Engl J Med. 2006 Aug 17; 355(7):733; author reply 733-4.
Score: 0.007
-
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025 Feb; 107(2):234-254.
Score: 0.006
-
Bae KT, Tao C, Feldman R, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Mrug M, Bennett WM, Harris PC, Srivastava A, Landsittel DP, Abebe KZ. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384.
Score: 0.005
-
Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, Mrug M, Braun WE, Steinman TI, Rahbari-Oskoui FF, Brosnahan GM, Bae KT, Landsittel D, Chebib FT, Yu AS, Torres VE, Harris PC. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
Score: 0.004
-
Grau L, Gitomer B, McNair B, Wolf M, Harris P, Brosnahan G, Torres V, Steinman T, Yu A, Chapman A, Chonchol M, Nowak KL. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656.
Score: 0.004
-
Bae KT, Shi T, Tao C, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Srivastava A, Irazabal MV, Abebe KZ, Harris PC, Landsittel DP. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651.
Score: 0.004
-
Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296.
Score: 0.004
-
Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
Score: 0.004
-
Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic?kidney disease. Kidney Int. 2017 02; 91(2):493-500.
Score: 0.003
-
Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84.
Score: 0.003
-
Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76.
Score: 0.003
-
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66.
Score: 0.003
-
Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 01; 307(11):F1198-206.
Score: 0.003
-
Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6.
Score: 0.003
-
Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov; 25(11):2399-418.
Score: 0.003
-
Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res. 2014 06; 55(6):1139-49.
Score: 0.003
-
Barone GW, Wright CF, Krause MW, Brosnahan GM, Portilla D, Banerjee S, McCowan TC, Culp WC, Yousaf M. Hemodialysis access success: beyond the operating room. Am J Surg. 2007 Nov; 194(5):668-71.
Score: 0.002
-
Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9.
Score: 0.001
-
Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000 Dec; 11(12):2285-2296.
Score: 0.001
-
Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Mar; 35(3):427-32.
Score: 0.001
-
Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999 May; 14(5):1113-6.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|